ES2222663T3 - Carbazoles sustituidos, procedimiento para su preparacion y su uso como inhibidores de spla2. - Google Patents

Carbazoles sustituidos, procedimiento para su preparacion y su uso como inhibidores de spla2.

Info

Publication number
ES2222663T3
ES2222663T3 ES99302941T ES99302941T ES2222663T3 ES 2222663 T3 ES2222663 T3 ES 2222663T3 ES 99302941 T ES99302941 T ES 99302941T ES 99302941 T ES99302941 T ES 99302941T ES 2222663 T3 ES2222663 T3 ES 2222663T3
Authority
ES
Spain
Prior art keywords
methyl
acid
oxyacetic
carbamoylcarbazol
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99302941T
Other languages
English (en)
Spanish (es)
Inventor
Benjamin Alan Anderson
Nicholas James Bach
Jolie Anne Bastian
Nancy Kay Harn
Richard Waltz Harper
Gary Alan Hite
Michael Dean Kinnick
Ho-Shen Lin
Richard James Loncharich
John Mcneill Mcgill
Edward David Mihelich
John Michael Morin Jr.
Michael Leroy Phillips
Michael Enrico Richett
Daniel Jon Sall
Jason Scott Sawyer
Richard Walter Schevitz
Robert Theodore Vasileff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2222663T3 publication Critical patent/ES2222663T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES99302941T 1998-04-17 1999-04-16 Carbazoles sustituidos, procedimiento para su preparacion y su uso como inhibidores de spla2. Expired - Lifetime ES2222663T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17
US62328 1998-04-17

Publications (1)

Publication Number Publication Date
ES2222663T3 true ES2222663T3 (es) 2005-02-01

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99302941T Expired - Lifetime ES2222663T3 (es) 1998-04-17 1999-04-16 Carbazoles sustituidos, procedimiento para su preparacion y su uso como inhibidores de spla2.
ES99302967T Expired - Lifetime ES2226286T3 (es) 1998-04-17 1999-04-16 Carbazales sustituidos, procedimiento para su preparacion y su uso como inhibidores de spla2.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99302967T Expired - Lifetime ES2226286T3 (es) 1998-04-17 1999-04-16 Carbazales sustituidos, procedimiento para su preparacion y su uso como inhibidores de spla2.

Country Status (30)

Country Link
EP (2) EP0950657B1 (https=)
JP (2) JP4435330B2 (https=)
KR (2) KR100586761B1 (https=)
CN (1) CN1149193C (https=)
AR (2) AR018186A1 (https=)
AT (2) ATE268756T1 (https=)
AU (2) AU753436B2 (https=)
BR (2) BR9901279A (https=)
CA (2) CA2269246C (https=)
CO (2) CO5031247A1 (https=)
CZ (2) CZ136999A3 (https=)
DE (2) DE69918590T2 (https=)
DK (1) DK0950657T3 (https=)
DZ (1) DZ2769A1 (https=)
EA (2) EA002347B1 (https=)
ES (2) ES2222663T3 (https=)
HU (2) HUP9901220A3 (https=)
ID (2) ID23761A (https=)
IL (2) IL129483A0 (https=)
NO (2) NO314400B1 (https=)
NZ (3) NZ335253A (https=)
PE (2) PE20000432A1 (https=)
PL (2) PL332565A1 (https=)
PT (1) PT950657E (https=)
SG (2) SG81977A1 (https=)
SI (1) SI0950657T1 (https=)
TR (2) TR199900853A2 (https=)
TW (1) TWI238160B (https=)
YU (2) YU19199A (https=)
ZA (2) ZA992772B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
JP2002542148A (ja) * 1998-12-21 2002-12-10 イーライ・リリー・アンド・カンパニー 敗血症の処置のための組み合わせ療法
JP2003505372A (ja) * 1999-07-19 2003-02-12 イーライ・リリー・アンド・カンパニー sPLA2インヒビター
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
WO2002000257A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for alzheimer's disease
DE60130891T2 (de) * 2000-06-29 2008-07-17 Anthera Pharmaceuticals Inc., San Mateo Heilmittel für krebs
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
EP1345898A2 (en) 2000-12-18 2003-09-24 Eli Lilly And Company Teracyclic carbazole derivates and their use as spla2 inhibitors
CA2441077A1 (en) 2001-03-28 2002-10-10 Eli Lilly And Company Substituted carbazoles as inhibitors of spla2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
MX2010010471A (es) 2008-03-26 2010-10-20 Daiichi Sankyo Co Ltd Derivado de tetrahidroisoquinolina novedoso.
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
WO2010084402A2 (en) * 2009-01-22 2010-07-29 Orchid Research Laboratories Ltd. Heterocyclic compounds as phosphodiesterase inhibitors
CA2757622A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
MX361692B (es) 2010-02-03 2018-12-13 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
CA2889642A1 (en) * 2012-11-30 2014-06-05 Ge Healthcare Limited Zinc halide mediated cyclization process leading to tricyclic indoles
KR20150088802A (ko) 2012-11-30 2015-08-03 지이 헬쓰케어 리미티드 트리시클릭 인돌 유도체의 결정화 방법
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5472978A (en) * 1991-07-05 1995-12-05 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
EP0779271B1 (en) * 1995-12-13 2001-08-01 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
CA2269203A1 (en) * 1996-10-30 1998-05-07 Nicholas James Bach Substituted tricyclics
EP1007056A1 (en) * 1997-09-26 2000-06-14 Eli Lilly And Company Method for the treatment of cystic fibrosis
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
DZ2769A1 (fr) 2003-12-01
HU9901221A (hu) 2000-04-28
EP0952149A2 (en) 1999-10-27
EP0950657A2 (en) 1999-10-20
PE20000432A1 (es) 2000-05-23
TR199900853A3 (tr) 1999-11-22
CA2269246C (en) 2009-08-25
EA199900301A3 (ru) 2000-04-24
JP4435330B2 (ja) 2010-03-17
EA199900303A2 (ru) 1999-10-28
AR018593A1 (es) 2001-11-28
JPH11322713A (ja) 1999-11-24
HUP9901220A3 (en) 2001-11-28
YU19199A (sh) 2002-08-12
NO991822L (no) 1999-10-18
AU2381999A (en) 1999-10-28
AU753436B2 (en) 2002-10-17
NO991822D0 (no) 1999-04-16
ATE268756T1 (de) 2004-06-15
CA2269262A1 (en) 1999-10-17
CZ137099A3 (cs) 1999-11-17
EA002816B1 (ru) 2002-10-31
NZ507564A (en) 2002-10-25
KR19990083233A (ko) 1999-11-25
SI0950657T1 (en) 2005-02-28
CA2269246A1 (en) 1999-10-17
PT950657E (pt) 2004-11-30
IL129485A0 (en) 2000-02-29
CO5011054A1 (es) 2001-02-28
DE69917833D1 (de) 2004-07-15
ID23761A (id) 2000-05-11
ES2226286T3 (es) 2005-03-16
ZA992772B (en) 2002-07-16
SG81977A1 (en) 2001-07-24
EP0952149A3 (en) 2001-08-16
ATE271037T1 (de) 2004-07-15
KR100586761B1 (ko) 2006-06-08
EA002347B1 (ru) 2002-04-25
YU18999A (sh) 2002-08-12
BR9901279A (pt) 2000-05-02
PE20000476A1 (es) 2000-06-02
TR199900853A2 (xx) 1999-11-22
JP2000026416A (ja) 2000-01-25
AR018186A1 (es) 2001-10-31
ID23287A (id) 2000-04-05
NZ335251A (en) 2000-11-24
IL129483A0 (en) 2000-02-29
EA199900301A2 (ru) 1999-10-28
PL332565A1 (en) 1999-10-25
NO314400B1 (no) 2003-03-17
NO991821D0 (no) 1999-04-16
ZA992771B (en) 2002-04-18
HU9901221D0 (en) 1999-06-28
TWI238160B (en) 2005-08-21
CN1149193C (zh) 2004-05-12
PL332566A1 (en) 1999-10-25
NO991821L (no) 1999-10-18
DE69918590T2 (de) 2005-07-21
EA199900303A3 (ru) 2000-04-24
TR199900843A2 (xx) 2000-02-21
EP0952149B1 (en) 2004-06-09
HU9901220D0 (en) 1999-06-28
NO312240B1 (no) 2002-04-15
KR19990083232A (ko) 1999-11-25
CZ136999A3 (cs) 1999-11-17
SG81976A1 (en) 2001-07-24
CO5031247A1 (es) 2001-04-27
EP0950657A3 (en) 2001-08-16
EP0950657B1 (en) 2004-07-14
HU9901220A (hu) 2000-04-28
NZ335253A (en) 2000-11-24
BR9902365A (pt) 2001-04-24
CN1253948A (zh) 2000-05-24
AU2381799A (en) 1999-10-28
DE69918590D1 (de) 2004-08-19
HUP9901221A3 (en) 2001-11-28
DK0950657T3 (da) 2004-11-22
DE69917833T2 (de) 2005-07-14
AU753547B2 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
ES2222663T3 (es) Carbazoles sustituidos, procedimiento para su preparacion y su uso como inhibidores de spla2.
ES2197204T3 (es) Inhibidores de spla2 1h-indol-1-funcionales.
ES2202560T3 (es) Triciclicos sustituidos.
US6177440B1 (en) Substituted tricyclics
ES2208685T3 (es) Inhibidores de indolizina spla2.
ES2229375T3 (es) Derivados del indol para el tratamiento de la osteoporosis.
JP2001503055A5 (https=)
ES2213668T3 (es) Compuestos triciclicos sustituidos utiles en enfermedades inducidas por spla2.
ES2263283T3 (es) Inhibidores de spla2 indol.
ES2236971T3 (es) Derivados del indol utiles, entre otras cosas, para el tratamiento de la osteoporosis.
ES2252497T3 (es) Derivados ciclohept(b)indol como inhibidores de spla2.
US6713645B1 (en) Substituted tricyclics
US6506758B2 (en) Indole derivatives useful A.O. for the treatment of osteoporosis
US6933313B2 (en) Substituted carbazoles as inhibitors of sPLA2
ES2264708T3 (es) Derivados tetraciclicos como inhibidores de la spla2.
HK1024911A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors
MXPA99003587A (es) Compuestos triciclicos substituidos